Kontoghiorghes G J, Sheppard L, Hoffbrand A V, Charalambous J, Tikerpae J, Pippard M J
J Clin Pathol. 1987 Apr;40(4):404-8. doi: 10.1136/jcp.40.4.404.
A novel iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, and desferrioxamine were compared for their ability to remove iron and for their site of action in iron release in rats. Repeated intraperitoneal injections of the chelators in rats with widespread tissue labelling by 59Fe derived from transferrin showed comparable 59Fe mobilisation by each chelator in normal and iron loaded rats. Specific labelling of a chelatable "cold" iron pool in hepatocytes by 59Fe derived from ferritin showed this pool to be equally accessible to parenteral doses of both chelators and also to oral 1,2-dimethyl-3-hydroxypyrid-4-one, which is an effective oral iron chelating agent that removes iron from parenchymal cells. This and other alpha-ketohydroxypyridines need further development as potential therapeutic agents in human iron overload.
一种新型铁螯合剂1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮与去铁胺在大鼠体内的铁清除能力及铁释放作用位点方面进行了比较。给经转铁蛋白来源的59Fe广泛标记组织的大鼠反复腹腔注射螯合剂,结果显示在正常和铁负荷大鼠中,每种螯合剂的59Fe动员能力相当。由铁蛋白来源的59Fe对肝细胞中可螯合的“冷”铁池进行特异性标记,结果表明该铁池对于两种螯合剂的肠外给药以及口服1,2 - 二甲基 - 3 - 羟基吡啶 - 4 - 酮(一种有效的口服铁螯合剂,可从实质细胞中清除铁)而言同样易于接近。这种及其他α - 酮羟基吡啶作为人类铁过载潜在治疗药物还需要进一步研发。